Biogen Inc. has successfully completed the acquisition of Human Immunology Biosciences (HI-Bio), a privately-held clinical-stage biotechnology firm focused on targeted therapies for patients suffering from severe immune-mediated diseases (IMDs). With the acquisition finalized, Biogen intends to integrate HI-Bio’s lead asset, Felzartamab, into its pipeline, underscoring its strengthened presence in immunology. Felzartamab has demonstrated promising results in several Phase 2 studies, including in IgA nephropathy (IgAN), antibody-mediated rejection (AMR), and primary membranous nephropathy (PMN). Biogen aims to advance Felzartamab to Phase 3 trials to address unmet medical needs in rare diseases. The collaboration is set to leverage Biogen’s global infrastructure and HI-Bio’s deep expertise to accelerate the development of innovative treatments.

Biotechnology, Pharmaceuticals,United States